A large U.S. study has found that adults diagnosed with cannabis use disorder, a clinical pattern of heavy, compulsive marijuana use, face a lung cancer risk nearly four times higher than matched peers without such a diagnosis.
The study, published in the journal Lung Cancer and highlighted by ScienceDaily on July 10, 2026, drew on 20 years of electronic medical record data from 67 U.S. health care organizations. After propensity score matching — a statistical technique used to create comparable groups — the researchers analyzed nearly 150,000 matched participants per group.
Adults with cannabis use disorder had a relative risk of developing lung or bronchus cancer of 3.87 times that of those without the disorder (RR = 3.87; 95% CI 3.43–4.38). The elevated risk persisted at one year of follow-up (RR 3.48) and at five years of follow-up (RR 3.92) after cannabis use disorder diagnosis, suggesting it was not an artifact of short-term observation.
The risk was consistent across all major histologic subtypes of lung cancer: small cell carcinoma (RR 2.70), adenocarcinoma (RR 2.54), squamous cell carcinoma (RR 2.90), and non-small cell lung cancer (RR 2.75). The fact that all major cancer types showed elevated risk is notable — it suggests a broad carcinogenic mechanism rather than one specific to a particular pathway.
Why This Matters
Cannabis is now legally sold for recreational use in 24 U.S. states, and its cultural acceptance has outpaced the development of rigorous longitudinal health data. The connection between tobacco smoking and lung cancer is well established, with tobacco smoke containing more than 70 known carcinogens. Cannabis smoke contains many of the same carcinogens — because combustion itself, not nicotine, is primarily responsible for most of tobacco smoke's carcinogenic properties.
But the research base for marijuana and lung cancer has historically been far weaker than for tobacco: smaller sample sizes, shorter follow-up periods, and confounding by concurrent tobacco use have all limited the evidence base. This new study — described by its authors as the most comprehensive U.S. data yet on the marijuana-lung cancer link — addresses some of those limitations through scale and methodological rigor.
One critical nuance: this study examined people with a formal clinical diagnosis of cannabis use disorder — a pattern of use that causes significant impairment or distress and meets specific diagnostic criteria. It does not characterize the risk for casual, infrequent cannabis users. A 40-year Swedish cohort study previously found that heavy cannabis use beginning in young adulthood was associated with a two-fold increased lung cancer risk even after adjusting for tobacco use and other confounders — the current study's larger magnitude may reflect the severity of the use pattern captured by the clinical disorder diagnosis.
What We Know So Far
The study, published in Lung Cancer on April 22, 2026, used the TriNetX US Collaborative Network — a large electronic health record database containing data from more than 118 million patients across 67 tertiary health care systems spanning 20 years.
Researchers compared a cohort of adults with a documented diagnosis of cannabis use disorder to a propensity score-matched comparison group without that diagnosis. The matching process accounts for demographic and clinical variables that might otherwise explain the difference in cancer rates — a methodological strength that distinguishes this study from earlier, smaller analyses.
The primary finding — an RR of 3.87 — reflects the overall risk at any point after diagnosis. Subgroup analysis by cancer type confirmed that all major lung cancer subtypes showed elevated risk, with relative risks ranging from 2.54 for adenocarcinoma to 2.90 for squamous cell carcinoma and 2.70 for small cell carcinoma.
The study does not establish the specific amount of marijuana use that drives the risk, nor does it disentangle concurrent tobacco use, vaping, or other inhalational exposures that may co-occur in people with cannabis use disorder. These are acknowledged limitations by the research team.
Where the Risk Is Most Concentrated
Cannabis use disorder is more prevalent in younger adults, men, and people in states where recreational cannabis is legally available and socially normalized. The states with the highest rates of adult cannabis use — California, Colorado, Oregon, Nevada, Washington, Michigan, Illinois, and Massachusetts — are also states where more users are likely to progress to heavier or more disordered patterns of use over time.
According to Brooks Udelsman, MD, a thoracic surgeon at USC's Keck Medicine and co-author of the study, scientists are still working to understand the biological mechanisms by which marijuana smoke causes lung cancer. The same combustion-related carcinogens found in tobacco smoke — including benzene, naphthalene, and vinyl chlorides — are present in marijuana smoke, and some studies suggest marijuana smoke deposits more tar per cigarette equivalent than tobacco smoke because users typically inhale more deeply and hold the smoke longer.
Adolescent cannabis use warrants particular attention. Adolescent cannabis use is rising in the context of legalization and cultural normalization, and the developing brain is particularly vulnerable to early initiation. The lung cancer consequences of early-initiation heavy use may not appear for decades — making current prevention efforts more important, not less.
What Doctors and Experts Say
The study authors, writing in Lung Cancer, noted that given the rising prevalence of cannabis use, further research is needed to clarify dose-response relationships and the biological mechanisms driving these associations, and that clinicians should consider these risks when advising patients about cannabis use.
Dr. Brooks Udelsman, a thoracic surgeon at Keck Medicine of USC, told ScienceDaily that while the relationship between tobacco smoking and lung cancer is well established, the picture with cannabis is far less clear, but growing evidence suggests heavy use may carry significant risks. He and his colleagues called for further studies to better understand the dose-response relationship.
Pharmacy Times, in its coverage of the study, emphasized that a cannabis use disorder phenotype was associated with increased odds of both small-cell and non-small-cell lung cancer, reinforcing concerns that heavy, chronic inhalational exposure may be clinically consequential.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Retrospective cohort study using propensity score matching
- Data source: TriNetX US Collaborative Network (118 million patients, 67 health care organizations, 20 years of data)
- Published in: Lung Cancer, April 22, 2026 (DOI: 10.1016/j.lungcan.2026.109421)
- Sample size: Approximately 150,000 matched participants per group
- Lead author affiliations: Keck School of Medicine, University of Southern California
- What it found: Cannabis use disorder associated with RR of 3.87 for lung or bronchus cancer; elevated risk consistent across all major histologic subtypes; risk remained elevated at 1-year and 5-year follow-up
- What it did not prove: A causal mechanism; dose-response relationship between marijuana use and lung cancer risk; that casual or infrequent cannabis use carries comparable risk; that concurrent tobacco use was fully excluded as a confounder (the study used propensity matching but not necessarily tobacco-naïve populations)
- Important distinction: Cannabis use disorder is a clinical diagnosis reflecting heavy, compulsive use patterns — not the same as occasional or recreational use
- What readers should know: Heavy, chronic marijuana smoking carries meaningful lung cancer risk signals. Casual or infrequent use is not directly addressed by this study. Combustion is the primary carcinogenic mechanism — alternative delivery methods such as edibles do not involve smoke inhalation.
Who Faces the Greatest Risk?
- Adults who smoke marijuana heavily and frequently — particularly daily or near-daily smokers
- People with a clinical diagnosis of cannabis use disorder
- Individuals who began heavy cannabis use in adolescence or young adulthood
- People who hold smoke in their lungs after inhalation — a common practice that increases carcinogen exposure
- Concurrent tobacco users, in whom the combined lung insult may be additive or synergistic
- Older adults who have been smoking cannabis for 20 or more years
Casual users — those who use marijuana occasionally without developing disordered patterns of use — are not well-represented in this study and should not assume the 3.87 relative risk applies directly to their situation.
Symptoms and Warning Signs to Watch For
Lung cancer often produces no symptoms in its earliest, most treatable stages. Symptoms that warrant prompt medical evaluation — particularly in anyone who smokes or has smoked marijuana or tobacco regularly — include:
- A new, persistent cough that does not resolve over several weeks
- Blood in sputum or coughing up blood
- Chest pain that worsens with deep breathing, coughing, or laughing
- Hoarseness or voice changes
- Shortness of breath that is new or worsening
- Unexplained weight loss
- Persistent fatigue
The American Cancer Society recommends annual low-dose CT lung cancer screening for adults ages 50 to 80who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Whether equivalent screening recommendations will emerge for heavy marijuana smokers is a question future research may address.
What You Can Do Now
- If you smoke marijuana regularly, discuss your lung health history and cancer risk with your primary care doctor — particularly if you also smoke or have smoked tobacco.
- If you experience any of the symptoms listed above — especially a new, persistent cough or unexplained weight loss — seek medical evaluation promptly.
- If you use marijuana for recreational or medical purposes, consider non-combustion delivery methods — such as vaporizers (using regulated, verified products), tinctures, or edibles — to avoid the carcinogenic effects of inhaled smoke. Note that vaping carries its own respiratory risks and is not without controversy.
- If you are concerned about your pattern of marijuana use, discuss it with a health-care provider. Cannabis use disorder is a recognized medical condition with effective treatments, including behavioral therapy.
- If you have a 20 pack-year smoking history from tobacco, ask your doctor about annual low-dose CT lung cancer screening , which is now a standard preventive service.
Cost and Access: What Patients Should Know
Low-dose CT lung cancer screening is covered at no cost-sharing under the Affordable Care Act's preventive services mandate for eligible adults who meet the smoking history and age criteria. Cannabis use disorder treatment — including counseling and, where appropriate, medication-assisted therapy — is covered under most insurance plans' behavioral health benefits.
For uninsured individuals who use marijuana heavily and are concerned about lung health, Federally Qualified Health Centers offer primary care evaluation at sliding-scale fees. Find one at findahealthcenter.hrsa.gov.
What Happens Next
The study authors called for further research to clarify the dose-response relationship between marijuana use and lung cancer and to identify the biological mechanisms driving the association. Future studies should ideally follow individuals from the point of cannabis initiation, better characterize concurrent tobacco use, and distinguish between inhaled and non-inhaled delivery methods.
As legal cannabis use expands, longitudinal health registries specifically tracking cannabis users are expected to provide cleaner data in the coming years. MedicalDaily will report on new findings in this area as they are published.
The Bottom Line
The largest U.S. study to date on marijuana and lung cancer found that people diagnosed with cannabis use disorder — heavy, compulsive users — face a lung cancer risk nearly four times higher than matched non-users. That risk applied across all major types of lung cancer and persisted at five-year follow-up. The study does not tell casual users what their risk is, and it does not establish a proven biological mechanism. But it is the strongest U.S. evidence yet that heavy marijuana smoking carries meaningful lung cancer risk — a finding that clinicians, heavy users, and public health agencies should take seriously as cannabis use continues to expand across the country.
